OTC Monograph Route More Onerous Than NDA Process – ONP Official
This article was originally published in The Tan Sheet
Executive Summary
Companies seeking to market OTC products should consider a new drug application versus the monograph route when both are options because NDAs will yield a "faster turnaround," said Office of Nonprescription Products Associate Director Susan Johnson
You may also be interested in...
FDA Mulls Adding Insect Repellent Combinations To Sunscreen Monograph
If FDA decides to include combination insect repellent/sunscreen drug products in the sunscreen monograph, some products could be forced to file new drug applications or face removal from the market
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement